Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Buenos Aires, Argentina.
Int J Oncol. 2012 Nov;41(5):1561-9. doi: 10.3892/ijo.2012.1611. Epub 2012 Aug 29.
Telomerase is the enzyme responsible for maintenance of the length of telomeres by addition of guanine-rich repetitive sequences. Telomerase activity is exhibited in gametes and stem and tumor cells. In human somatic cells, proliferation potential is strictly limited and senescence follows approximately 50-70 cell divisions. In most tumor cells, on the contrary, replication potential is unlimited. The key role in this process of the system of the telomere length maintenance with involvement of telomerase is still poorly studied. Undoubtedly, DNA polymerase is not capable of completely copying DNA at the very ends of chromosomes; therefore, approximately 50 nucleotides are lost during each cell cycle, which results in gradual telomere length shortening. Critically short telomeres cause senescence, following crisis and cell death. However, in tumor cells the system of telomere length maintenance is activated. Much work has been done regarding the complex telomere/telomerase as a unique target, highly specific in cancer cells. Telomeres have additional proteins that regulate the binding of telomerase. Telomerase, also associates with a number of proteins forming the sheltering complex having a central role in telomerase activity. This review focuses on the structure and function of the telomere/telomerase complex and its altered behavior leading to disease, mainly cancer. Although telomerase therapeutics are not approved yet for clinical use, we can assume that based on the promising in vitro and in vivo results and successful clinical trials, it can be predicted that telomerase therapeutics will be utilized soon in the combat against malignancies and degenerative diseases. The active search for modulators is justified, because the telomere/telomerase system is an extremely promising target offering possibilities to decrease or increase the viability of the cell for therapeutic purposes.
端粒酶是负责通过添加富含鸟嘌呤的重复序列来维持端粒长度的酶。端粒酶活性存在于配子和干细胞和肿瘤细胞中。在人类体细胞中,增殖潜力受到严格限制,大约在 50-70 次细胞分裂后衰老。相反,在大多数肿瘤细胞中,复制潜力是无限的。在这个涉及端粒酶的端粒长度维持系统中,关键作用仍然研究不足。毫无疑问,DNA 聚合酶不能完全复制染色体末端的 DNA;因此,在每个细胞周期中大约丢失 50 个核苷酸,导致端粒逐渐缩短。临界短端粒导致衰老,随后是危机和细胞死亡。然而,在肿瘤细胞中端粒长度维持系统被激活。关于复杂的端粒/端粒酶作为一个独特的靶点,在癌细胞中高度特异的研究已经做了很多工作。端粒还有调节端粒酶结合的其他蛋白质。端粒酶还与许多形成庇护复合物的蛋白质结合,在端粒酶活性中起核心作用。这篇综述重点介绍端粒/端粒酶复合物的结构和功能及其改变的行为导致疾病,主要是癌症。尽管端粒酶治疗剂尚未获得临床批准,但我们可以假设,基于有希望的体外和体内结果和成功的临床试验,它可以预测端粒酶治疗剂将很快用于对抗恶性肿瘤和退行性疾病。积极寻找调节剂是合理的,因为端粒/端粒酶系统是一个非常有前途的靶点,为治疗目的提供了降低或增加细胞活力的可能性。